We also found that 20 neoantigens occurring in more than 80% of NDMM samples were preferentially presented by HLA-C alleles (Fig. 2D), suggesting neoantigens presented by HLA-C alleles could be prioritized for cancer vaccine development. The gene discussed is HLA-C; the disease is cancer.